Financial Statements and Highlights | Takeda Investor Relations
Loading feed metadata...
Sign up for our investors newsletter
Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planetSign up
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
February 12, 2024
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
February 8, 2024